Conservative treatment for breast cancer of limited extent. Results of a randomized trial.
Umberto Veronesi(Fondazione IRCCS Istituto Nazionale dei Tumori), R Zucali(Fondazione IRCCS Istituto Nazionale dei Tumori), Roberto Saccozzi(Fondazione IRCCS Istituto Nazionale dei Tumori), Alberto Luini(Institute for Experimental Endocrinology and Oncology), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Giuseppe Muscolino(University of Messina), Marco Greco(Hospital Clínico Universitario de Valencia), A Rasponi
PubMed
February 22, 1982
Cited by 7
Related Papers
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
|The Lancet Oncology|2017|780
Breast Cancer
|New England Journal of Medicine|1992|701
Inefficacy of Immediate Node Dissection in Stage 1 Melanoma of the Limbs
|New England Journal of Medicine|1977|667
Interleukin-12: Biological Properties and Clinical Application
|Clinical Cancer Research|2007|606